Mycophenolate mofetil contributes to downregulation of the hippocampal interleukin type 2 and 1β mediated PI3K/AKT/mTOR pathway hyperactivation and attenuates neurobehavioral comorbidities in a rat model of temporal lobe epilepsy.

MLA

Mazumder, Arindam Ghosh, et al. “Mycophenolate Mofetil Contributes to Downregulation of the Hippocampal Interleukin Type 2 and 1β Mediated PI3K/AKT/MTOR Pathway Hyperactivation and Attenuates Neurobehavioral Comorbidities in a Rat Model of Temporal Lobe Epilepsy.” Brain, Behavior, and Immunity, vol. 75, Jan. 2019, pp. 84–93. EBSCOhost, https://doi.org/10.1016/j.bbi.2018.09.020.

APA

Mazumder, A. G., Patial, V., & Singh, D. (2019). Mycophenolate mofetil contributes to downregulation of the hippocampal interleukin type 2 and 1β mediated PI3K/AKT/mTOR pathway hyperactivation and attenuates neurobehavioral comorbidities in a rat model of temporal lobe epilepsy. Brain, Behavior, and Immunity, 75, 84–93. https://doi.org/10.1016/j.bbi.2018.09.020

Chicago

Mazumder, Arindam Ghosh, Vikram Patial, and Damanpreet Singh. 2019. “Mycophenolate Mofetil Contributes to Downregulation of the Hippocampal Interleukin Type 2 and 1β Mediated PI3K/AKT/MTOR Pathway Hyperactivation and Attenuates Neurobehavioral Comorbidities in a Rat Model of Temporal Lobe Epilepsy.” Brain, Behavior, and Immunity 75 (January): 84–93. doi:10.1016/j.bbi.2018.09.020.